VOLUME 48, ISSUE 1, January 2012 - Get the newsletter as PDF here

EJC EUROFILE: A second chance to influence the Clinical Trials Directive

The European Commission has given its clearest indication yet of likely changes to the EU law governing clinical trials. Academia and the medical community is mobilising to make its voice heard as the Commission moves to fill in the detail...MORE

EJC INTERVIEW:  Elderly breast cancer patients ‘risk treatment discrimination’

Women diagnosed with breast cancer late in life “are at risk of being under-treated, which is leading to worse breast cancer outcomes than among younger women.”  Lead author Christos Markopoulos (Athens University Medical School) discusses the implications of the new research...MORE

EJC NEWS FOCUS

Some combinations of targeted agents in hormone-sensitive breast cancer may dramatically increase progression-free survival, according to results from the CLEOPATRA and BOLERO-2 trials, presented at the recent San Antonio Breast Cancer Symposium. Also at the meeting, previous confusion about the role of bisphosphonates in the adjuvant setting may have been resolved by new data. Rob Coleman (University of Sheffield, UK) was there, and in this month’s EJC News Focus, he discusses the implications of the new data with Helen Saul...MORE 

Edited by Helen Saul. 
Telephone: +44 1865 843340
email: h.saul@elsevier.com